Pioglitazone

CAS No:
111025-46-8 Categories: , ,
  • #LGM Pharma is a Pioglitazone CAS# 111025-46-8 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 111025-46-8
  • AHFC code: 08:20.3
  • Synonyms: Pioglitazona [INN-Spanish] Pioglitazone [Ban:Inn] pioglitazone HCl Pioglitazone Hydrochloride Pioglitazonum [INN-Latin]
  • ATC Code: A10BG03
  • Chemical Formula: C10H17N3S
  • Molecular Weight: 356.439
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB01132 (APRD00653)
  • SMILES: CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
  • InChl: HYAFETHFCAUJAY-UHFFFAOYSA-N
  • PubChem: 4829
  • IUPAC: 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione

Additional Details

Indication:
Treatment of Type II diabetes mellitus
Pharmacodynamics:
Pioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent.
Mode of Action:
Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic _ cells.
Metabolism:
Hepatic
Toxicity:
Hypogycemia; LD50=mg/kg (orally in rat)
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos